YAP1 and cancer: Indeed, numerous compounds that target YAP/TAZ-TEAD have been described (reviewed in [21]) and three TEAD inhibitors (VT3989, IK-930, IAG933) have recently entered early-phase clinical trials in cancer patients (NCT04665206, NCT05228015, and NCT04857372).